DKSH Partners With RedShift BioAnalytics in Four Key Markets in Asia Pacific

Zurich, March, 31 2022– DKSH Business Unit Technology has entered a partnership with RedShift BioAnalytics (RedShiftBio^Ⓡ) a provider of next-generation platform technology enabling measurements of previously undetectable structure changes in biomolecules. DKSH will provide marketing, sales, and after-sales services in Korea, Taiwan, Singapore, and Thailand.

RedShiftBio’s flagship instrument, the AQS³pro, provides users with in-depth structural information in a single automated analysis through a powerful analytical technique called Microfluidic Modulation Spectroscopy (MMS). MMS overcomes many of the limitations of traditional spectroscopy-based technologies with ultrasensitive and highly reproducible structural measurements of proteins and other biomolecules. It can be used for a wide range of applications from formulation development of Monoclonal Antibodies (mAb)-based biotherapeutics to robust measurements of Antibody-Drug Conjugates (ADCs), Adeno Associated Viruses (AAVs), and messenger RiboNucleic Acid (mRNA).

“The successful adoption of the AQS³pro throughout the biopharmaceutical industry highlights the critical value our technology provides with ultra-sensitive measurements of biomolecule structure,” said Julien Bradley, Chief Executive Officer of RedShiftBio. “Our partnership with DKSH will expand global access to our MMS technology, providing more users with a new level of insight to accelerate and de-risk drug development.”

Marco Farina Senior Director, Business Development, Business Unit Technology, DKSH, commented: “Expanding our life science portfolio and accelerating our growth for the business are key initiatives for DKSH’s Business Unit Technology. Partnering with RedShiftBio complements our workflow of protein characterization.  We are excited to introduce RedShiftBio’s leading solutions to our customers.”